The US Pharmacopeia (USP) has proposed a revision to General Chapter <660> Container—Glass, which provides specifications for ...

GlobalData’s clinical trials dashboard is powered by the Pharma Intelligence Center, which boasts a highly comprehensive source of Clinical Trials collated from numerous government, non-government ...

Public markets are showing early signs of reopening, as Q4 2025 saw a 157% increase in IPO deal volume compared to Q4 2024.

AbbVie’s lost exclusivity for Humira is offset by immunology and neurology sales, diversified by its emerging oncology ...

Johnson & Johnson’s (J&J) Caplyta (lumateperone) plus antidepressants nearly doubled the likelihood of remission after six ...

Agenus has completed a $141m strategic collaboration with Zydus Lifesciences to accelerate the global development and ...

Novo Nordisk is positioning itself as a long‑term leader across multiple obesity segments rather than relying on a single ...

Eli Lilly highlighted 2025 as the rollout year for obesity drugs, with Mounjaro at the forefront of its weight-loss portfolio ...

The funding aims to encourage innovation in Europe amid concerns that innovation across the continent is lagging behind China ...

The UK is now the first nation to approve the maximum dose 7.2mg Wegovy regimen, which will be used to treat obesity.

While the FDA came out on top over the EMA in terms of approvals, both agencies greenlighted fewer new drugs than in 2024.

Clinical and commercial quality controls are eased as the FDA looks to expedite therapy approvals in areas of unmet need.